SLC2A5 and lung adenocarcinoma: Furthermore, Weng et al. demonstrated that overexpression of SLC2A5 is associated with poor prognosis in lung adenocarcinoma, and inhibition of GLUT5 could increase the sensitivity of lung adenocarcinoma cells to the chemotherapeutic drug paclitaxel 33.